The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
News Medical on MSN1d
Opioid δ-receptor agonists show promise for treating IBS-like symptomsResearch reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can ...
Patients with glaucoma who are using prostaglandin F (FP) receptor agonists to control their disease may experience ...
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
HealthDay on MSN1d
Study Finds Exenatide Not Beneficial for Parkinson DiseaseThe glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback